Katie Kennedy
About Katie Kennedy
Katie Kennedy is a QA Senior Specialist at Bristol-Myers Squibb in New York, with over 18 years of experience in quality control and quality assurance within the pharmaceutical industry.
Title: QA Senior Specialist
Katie Kennedy holds the position of QA Senior Specialist at Bristol-Myers Squibb. Katie's current responsibilities at this New York-based role involve ensuring the highest standards of quality assurance within the pharmaceutical company. Her extensive experience in the industry supports her significant contributions to maintaining and improving quality systems and processes.
Company: Bristol-Myers Squibb
Katie Kennedy has been a dedicated employee at Bristol-Myers Squibb for over 18 years. Throughout her tenure, she has advanced through various roles in quality control and quality assurance, reflecting her growth and adaptability within the company. Currently, she contributes as a QA Senior Specialist, continuing her commitment to excellence in the pharmaceutical industry.
Previous Roles at Bristol-Myers Squibb
Before her current role, Katie Kennedy served as a QC Manager at Bristol-Myers Squibb from 2014 to 2015. Prior to that, she worked for 11 years in multiple roles including QC Dept, Analyst, Team Lead, and QC Planner. Her long-term engagement with the company underscores her extensive background and expertise in quality control and assurance.
Employment at Merck
Katie Kennedy began her career in the pharmaceutical industry as a QC Analyst at Merck, where she worked from 2001 to 2003. This early role provided her with foundational experience in quality control, preparing her for future responsibilities and advancement within the industry.
Education and Expertise
Katie Kennedy studied at the Institute of Technology, Sligo from 2014 to 2015. She also attended Dublin City University from 1997 to 2011. Her academic background, combined with her practical experience, has equipped her with thorough expertise in quality assurance and control, making her a valuable asset to Bristol-Myers Squibb.